Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.02, Bloomberg Earnings reports. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same period in the prior year, the business posted $0.30 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Sucampo Pharmaceuticals updated its FY17 guidance to $1.10-1.15 EPS.

COPYRIGHT VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/sucampo-pharmaceuticals-inc-scmp-releases-quarterly-earnings-results-beats-expectations-by-0-02-eps/1674045.html.

Several equities research analysts have recently weighed in on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. UBS AG reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Mizuho downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $14.00 to $12.00 in a report on Tuesday, October 3rd. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Finally, Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $16.50.

In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jones W. Bryan bought 4,700 shares of the business’s stock in a transaction on Friday, August 4th. The stock was purchased at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now owns 4,700 shares of the company’s stock, valued at $49,820. The disclosure for this purchase can be found here. 4.13% of the stock is owned by insiders.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.